Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment

Abstract

Oncolytic viruses (OVs) are at the forefront of biologicals for cancer treatment. They represent a diverse landscape of naturally occurring viral strains and genetically modified viruses that, either as single agents or as part of combination therapies, are being evaluated in preclinical and clinical settings. As the field gains momentum, the research on OVs has been shifting efforts to expand our understanding of the complex interplay between the virus, the tumor and the immune system, with the aim of rationally designing more efficient therapeutic interventions. Nowadays, the potential of an OV platform is no longer defined exclusively by the targeted replication and cancer cell killing capacities of the virus, but by its contribution as an immunostimulator, triggering the transformation of the immunosuppressive tumor microenvironment (TME) into a place where innate and adaptive immunity players can efficiently engage and lead the development of tumor-specific long-term memory responses. Here we review the immune mechanisms and host responses induced by ssRNA(-) (negative-sense single-stranded RNA) viruses as OV platforms. We focus on two ssRNA(-) OV candidates: Newcastle disease virus (NDV), an avian paramyxovirus with one of the longest histories of utilization as an OV, and influenza A (IAV) virus, a well-characterized human pathogen with extraordinary immunostimulatory capacities that is steadily advancing as an OV candidate through the development of recombinant IAV attenuated platforms.

Keywords

Oncolytic virus / NDV / IAV / virotherapy / paramyxovirus / orthomyxovirus / ssRNA(-) / immunotherapy / cancer vaccine / ICD / in situ vaccination / tumor microenvironment

References

[1] Shatola A,Kamangar E.Spontaneous regression of non-small cell lung cancer: a case report and literature review.Cureus2020;12:e6639 PMCID:PMC7011577

[2] Taqi AM,Yakubu AM.Regression of hodgkin’s disease after measles.Lancet1981;1:1112

[3] George D.The influence of complicating disease upon leukæmia.Am J Med Sci1904;127:563-92

[4] Radha G.The spontaneous remission of cancer: current insights and therapeutic significance.Transl Oncol2021;14:101166 PMCID:PMC8271173

[5] Alberts P,Rasa A,Venskus D.The advent of oncolytic virotherapy in oncology: the rigvir® story.Eur J Pharmacol2018;837:117-26

[6] Guo W.Development of gene therapeutics for head and neck cancer in China: from bench to bedside.Hum Gene Ther2018;29:180-7

[7] Kaufman HL,Iodice G.Talimogene laherparepvec: moving from first-in-class to best-in-class.Front Mol Biosci2022;9:834841 PMCID:PMC8901478

[8] Sugawara K,Ito H,Seto Y.Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.Mol Ther Oncolytics2021;22:129-42 PMCID:PMC8413837

[9] Yun CO,Yoon AR.Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Front Immunol2022;13:953410 PMCID:PMC9458317

[10] Tang D,Berghe TV,Kroemer G.The molecular machinery of regulated cell death.Cell Res2019;29:347-64 PMCID:PMC6796845

[11] Bommareddy PK,Kaufman HL.Integrating oncolytic viruses in combination cancer immunotherapy.Nat Rev Immunol2018;18:498-513

[12] Wang L,Cheng Z.Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.J Immunother Cancer2022;10:e004167 PMCID:PMC9157365

[13] Galluzzi L,Warren S.Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.J Immunother Cancer2020;8:e000337

[14] Desfarges S.Viral integration and consequences on host gene expression. In: Witzany G, editor. Viruses: essential agents of life. Dordrecht: Springer Netherlands; 2012. pp. 147-75.

[15] Wang B,Li D.Newcastle disease virus infection induces activation of the NLRP3 inflammasome.Virology2016;496:90-6

[16] Ginting TE,Larasati YO,Suriapranata IM.Antiviral interferons induced by Newcastle disease virus (NDV) drive A tumor-selective apoptosis.Sci Rep2019;9:15160 PMCID:PMC6806003

[17] Wilden H,Zawatzky R.Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus.Int J Oncol2009;34:971-82

[18] Xu Q,Wang W.Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.Int J Cancer2020;146:531-41

[19] Shao X,Guo X.STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells.Front Oncol2019;9:436 PMCID:PMC6548873

[20] Jarahian M,Fournier P.Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.J Virol2009;83:8108-21 PMCID:PMC2715740

[21] Liang Y,Liang S,Gao LX.The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB.PLoS One2017;12:e0178746 PMCID:PMC5470681

[22] Burke S,Elder MJ.Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.Cancer Immunol Immunother2020;69:1015-27 PMCID:PMC7230062

[23] Oseledchyk A,Gigoux M.Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.Oncotarget2018;9:28702-16 PMCID:PMC6033351

[24] Zamarin D,Subudhi SK.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Sci Transl Med2014;6:226ra32 PMCID:PMC4106918

[25] Tanaka M,Kikuchi Y,Kaneda Y.Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.Int J Cancer2010;126:1982-91

[26] Matsushima-Miyagi T,Nomura M.TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.Clin Cancer Res2012;18:6271-83

[27] Chandrahekhar P.Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.Science2003;299:1033-6

[28] Fujihara A,Miki T.Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.Cancer Immunol Immunother2008;57:73-84

[29] Matveeva OV,Netesov SV,Chumakov PM.Mechanisms of oncolysis by paramyxovirus sendai.Acta Nat2015;7:6-16 PMCID:PMC4463408

[30] Saga K.Oncolytic sendai virus-based virotherapy for cancer: recent advances.Oncolytic Virother2015;4:141-7 PMCID:PMC4918391

[31] Achard C,Bruni D.Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.Oncoimmunology2017;6:e1261240 PMCID:PMC5283625

[32] Tan DQ,Ohba K,Ichiyama K.Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.Eur J Immunol2016;46:919-928

[33] Zhang Y,Dey A.Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.J Immunol2012;188:1002-10

[34] Berchtold S,Weiland T.Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.J Virol2013;87:3484-501 PMCID:PMC3592150

[35] Aref S,Fielding A.Measles to the rescue: a review of oncolytic measles virus.Viruses2016;8:294 PMCID:PMC5086626

[36] Engeland CE.Measles virus as an oncolytic immunotherapy.Cancers2021;13:544

[37] Donnelly OG,Steele L.Measles virus causes immunogenic cell death in human melanoma.Gene Ther2013;20:7-15 PMCID:PMC3378495

[38] Rajaraman S,Ghosh M.Measles virus-based treatments trigger a pro-inflammatory cascade and a distinctive immunopeptidome in glioblastoma.Mol Ther Oncolytic2019;12:147-61 PMCID:PMC6365369

[39] Guillerme JB,Roulois D.Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.Clin Cancer Res2013;19:1147-58

[40] Gauvrit A,Sapede-Peroz C,Tangy F.Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.Cancer Res2008;68:4882-92

[41] Boisgerault N,Pouliquen D.Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.Biomed Res Int2013;2013:387362 PMCID:PMC3613059

[42] Wang B,Guo Q.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Oncotarget2015;6:16019-30 PMCID:PMC4599253

[43] Javaheri A,Mena I,Cuadrado-Castano S.Avian paramyxovirus 4 antitumor activity leads to complete remissions and long-term protective memory in preclinical melanoma and colon carcinoma models.Cancer Res Commun2022;2:602-15 PMCID:PMC9351398

[44] Rieder M.Rhabdovirus evasion of the interferon system.J Interferon Cytokine Res2009;29:499-509

[45] Hornung V,Kim S.5′-triphosphate RNA is the ligand for RIG-I.Science2006;314:994-7

[46] Shi Z,Sanchez A.A novel toll-like receptor that recognizes vesicular stomatitis virus.J Biol Chem2011;286:4517-24 PMCID:PMC3039399

[47] Georgel P,Kunz S.Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway.Virology2007;362:304-13

[48] Barchet W,Odermatt B,Colonna M.Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo.J Exp Med2002;195:507-16 PMCID:PMC2193622

[49] Swiecki M.Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.Immunol Rev2010;234:142-62 PMCID:PMC3507434

[50] Lund JM,Sato A.Recognition of single-stranded RNA viruses by Toll-like receptor 7.Proc Natl Acad Sci USA2004;101:5598-603 PMCID:PMC397437

[51] Akira S,Takeuchi O.Pathogen recognition and innate immunity.Cell2006;124:783-801

[52] Melzer MK,Altomonte J.Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “hammer” and “anvil”.Biomedicines2017;5:8 PMCID:PMC5423493

[53] Guo ZS,Bartlett DL.Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity.Front Oncol2014;4:74 PMCID:PMC3989763

[54] Wongthida P,Galivo F.Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.Cancer Res2010;70:4539-49 PMCID:PMC3896099

[55] Diaz RM,Kottke T.Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.Cancer Res2007;67:2840-8

[56] Hastie E.Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.J Gen Virol2012;93:2529-45 PMCID:PMC4091291

[57] Pol JG,Bridle BW.Development and applications of oncolytic Maraba virus vaccines.Oncolytic Virother2018;7:117-28 PMCID:PMC6263248

[58] Bourgeois-Daigneault MC,Aitken AS.Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.Sci Transl Med2018;10:eaao1641

[59] Atherton MJ,Tzelepis F.Transforming the prostatic tumor microenvironment with oncolytic virotherapy.Oncoimmunology2018;7:e1445459 PMCID:PMC5993491

[60] Place DE,Kanneganti TD.PANoptosis in microbial infection.Curr Opin Microbiol2021;59:42-9 PMCID:PMC7438227

[61] Masemann D,Kuhlencord M.Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.Oncoimmunology2018;7:e1423171 PMCID:PMC5927530

[62] Wei J,Lata R.Influenza a infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.J Immunol2010;185:6013-22

[63] Rehwinkel J.RIG-I-like receptors: their regulation and roles in RNA sensing.Nat Rev Immunol2020;20:537-51 PMCID:PMC7094958

[64] Kawasaki T.Toll-like receptor signaling pathways.Front Immunol2014;5:461 PMCID:PMC4174766

[65] Burman B,Zamarin D.Newcastle disease virus at the forefront of cancer immunotherapy.Cancers2020;12:3552 PMCID:PMC7761210

[66] Malogolovkin A,Egorov A,Ivanov R.Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes.Viruses2021;13:1271 PMCID:PMC8309967

[67] Schirrmacher V.Fifty years of clinical application of newcastle disease virus: time to celebrate!.Biomedicines2016;4:16 PMCID:PMC5344264

[68] Hines NL.Avian paramyxovirus serotype-1: a review of disease distribution, clinical symptoms, and laboratory diagnostics.Vet Med Int2012;2012:708216 PMCID:PMC3345259

[69] Dortmans JC,Rottier PJ.Virulence of Newcastle disease virus: what is known so far?.Vet Res2011;42:122 PMCID:PMC3269386

[70] Panda A,Elankumaran S,Samal SK.Role of fusion protein cleavage site in the virulence of Newcastle disease virus.Microb Pathog2004;36:1-10 PMCID:PMC7125746

[71] Cuadrado-Castano S,García-Sastre A.The therapeutic effect of death: Newcastle disease virus and its antitumor potential.Virus Res2015;209:56-66 PMCID:PMC4630136

[72] Zhang WX,He Y.Promoter structures and differential responses to viral and non-viral inducers of chicken melanoma differentiation-associated gene 5.Mol Immunol2016;76:1-6 PMCID:PMC7127162

[73] Oh SW,Wakimoto M.Leader-containing uncapped viral transcript activates RIG-I in antiviral stress granules.PLoS Pathog2016;12:e1005444

[74] Fournier P,Schirrmacher V.Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus.Int J Oncol2012;40:287-98

[75] Kumar S,Mishra S.IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.Cell Death Dis2015;6:e1758 PMCID:PMC4669701

[76] Schirrmacher V.Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic newcastle disease virus.Biomedicines2022;10:562 PMCID:PMC8945571

[77] Gao P,Fan L.Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome.Vet Res2020;51:53 PMCID:PMC7156904

[78] Platanias LC.Mechanisms of type-I- and type-II-interferon-mediated signalling.Nat Rev Immunol2005;5:375-86

[79] Cuadrado-Castano S,Mansour M.Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.Mol Cancer Ther2015;14:1247-58 PMCID:PMC4425597

[80] Shan P,Xie S.NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.J Cell Biochem2021;122:3-15

[81] Morla S,Kumar S.Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: a probable role of β-catenin and matrix metalloproteinase-7.Sci Rep2019;9:10882 PMCID:PMC6659693

[82] Wang JY,Dai SZ.Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity.J Immunother Cancer2022;10:e003950 PMCID:PMC8905871

[83] Liao Y,Mao X.RIP1 is a central signaling protein in regulation of TNF-α/TRAIL mediated apoptosis and necroptosis during Newcastle disease virus infection.Oncotarget2017;8:43201-17 PMCID:PMC5522139

[84] Koks CA,Ehrhardt M.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.Int J Cancer2015;136:E313-25

[85] Nan FL,Nan WL.Newcastle disease virus inhibits the proliferation of T cells induced by dendritic cells in vitro and in vivo.Front Immunol2020;11:619829 PMCID:PMC7942023

[86] Zhao L,Shi X.Dendritic cells loaded with the lysate of tumor cells infected with Newcastle disease virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells.Oncol Lett2018;16:1180-8 PMCID:PMC6063031

[87] Fournier P,Wilden H.Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.Int J Oncol2012;40:840-50

[88] Duong E,Lutz E.Type I interferon activates MHC class I-dressed CD11b⁺ conventional dendritic cells to promote protective anti-tumor CD8⁺ T cell immunity.Immunity2022;55:308-323.e9

[89] Tan L,Qiao C.NDV entry into dendritic cells through macropinocytosis and suppression of T lymphocyte proliferation.Virology2018;518:126-35

[90] Bai L,Fiola C,Schirrmacher V.Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients.Int J Oncol2002;21:685-94

[91] Jensen S.Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion.J Virol2012;86:2900-10 PMCID:PMC3302314

[92] Bronte G,De Matteis S.High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: an exploratory analysis.Front Immunol2022;13:866561 PMCID:PMC9043492

[93] Kumar V,Tcyganov E.The nature of myeloid-derived suppressor cells in the tumor microenvironment.Trends Immunol2016;37:208-20 PMCID:PMC4775398

[94] Lim HX,Poh CL.Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers.Int J Mol Sci2020;21:3599 PMCID:PMC7279333

[95] Meng G,Chen A.Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.Br J Cancer2020;122:111-20 PMCID:PMC6964686

[96] Liang S,Liang Y,Zhang L.Killing Effects of IFN R^-/- mouse NK cells activated by HN protein of NDV on mouse hepatoma cells and possible mechanism with Syk and NF-κB.Anat Rec2019;302:1718-25 PMCID:PMC6771794

[97] Ricca JM,Walther T.Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy.Mol Ther2018;26:1008-19 PMCID:PMC6079372

[98] Ge Z,Zhang Z.Mechanism of tumor cells escaping from immune surveillance of NK cells.Immunopharmacol Immunotoxicol2020;42:187-98

[99] Zamarin D,Sadekova S.PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.J Clin Invest2018;128:1413-28

[100] Krabbe T,Groll T.Adoptive T cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma.Cancers2021;13:1044 PMCID:PMC7958625

[101] Matveeva OV,Shabalina SA.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Mol Ther Oncolytics2015;2:15011- PMCID:PMC4667958

[102] Termeer CC,Bröcker EB.Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.Cancer Gene Ther2000;7:316-23

[103] Ertel C,Emmerson PT,von Hoegen P.Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.Eur J Immunol1993;23:2592-6

[104] González-Navajas JM,Yang S.The impact of tregs on the anticancer immunity and the efficacy of immune checkpoint inhibitor therapies.Front Immunol2021;12:625783 PMCID:PMC7952426

[105] Duc Dang A,Hai Vu H.Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.Vaccine2022;40:3621-32 PMCID:PMC9106407

[106] Millar EV,Barin B.Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: a phase 2 vaccine trial among US Army Infantry trainees.Vaccine2021;39:3179-88

[107] Meng Q,Zhong L.Advances in the study of antitumour immunotherapy for newcastle disease virus.Int J Med Sci2021;18:2294-302 PMCID:PMC8100649

[108] Wheelock EF.Observations on the repeated administration of viruses to a patient with acute leukemia.N Engl J Med1964;271:645-51

[109] AstraZeneca. An open-label, phase 1 study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of MEDI9253, a recombinant Newcastle disease virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT04613492 [Last accessed on 3 Apr 2023]

[110] Long JS,Haslam SM.Host and viral determinants of influenza a virus species specificity.Nat Rev Microbiol2019;17:67-81

[111] Bouvier NM.The biology of influenza viruses.Vaccine2008;26 Suppl 4:D49-53 PMCID:PMC3074182

[112] Iwasaki A.Innate immunity to influenza virus infection.Nat Rev Immunol2014;14:315-28 PMCID:PMC4104278

[113] Ryu S.Human influenza epidemiology.Cold Spring Harb Perspect Med2021;11:a038356 PMCID:PMC8634793

[114] Nuwarda RF,Kayser V.An overview of influenza viruses and vaccines.Vaccines2021;9:1032 PMCID:PMC8473132

[115] Kasloff SB,Silic-Benussi M,Ciminale V.Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.J Virol2014;88:9321-34 PMCID:PMC4136238

[116] Gao Q.Rewiring the RNAs of influenza virus to prevent reassortment.Proc Natl Acad Sci USA2009;106:15891-6 PMCID:PMC2747214

[117] Mehrbod P,Alizadeh J.The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.Virulence2019;10:376-413 PMCID:PMC6527025

[118] Atkin-Smith GK,Chen W.The induction and consequences of influenza a virus-induced cell death.Cell Death Dis2018;9:1002 PMCID:PMC6156503

[119] Lee S,Noguchi M,Kawaguchi A.Influenza a virus infection triggers pyroptosis and apoptosis of respiratory epithelial cells through the type I interferon signaling pathway in a mutually exclusive manner.J Virol2018;92:e00396-18 PMCID:PMC6026744

[120] Zhirnov OP,Wolff T.NS1 protein of influenza a virus down-regulates apoptosis.J Virol2002;76:1617-25 PMCID:PMC135891

[121] Brydon EW,Sweet C.Role of apoptosis and cytokines in influenza virus morbidity.FEMS Microbiol Rev2005;29:837-50

[122] Lu X,Li Y,Liu Q.The PI3K/Akt pathway inhibits influenza a virus-induced Bax-mediated apoptosis by negatively regulating the JNK pathway via ASK1.J Gen Virol2010;91:1439-49

[123] Dhanasekaran DN.JNK signaling in apoptosis.Oncogene2008;27:6245-51 PMCID:PMC3063296

[124] Xie Y,Shi L.Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer.J Clin Invest2020;130:2111-28 PMCID:PMC7108921

[125] Choi ME,Ryter SW.Necroptosis: a crucial pathogenic mediator of human disease.JCI Insight2019;4:128834 PMCID:PMC6693822

[126] Meng MB,Cui YL.Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.Oncotarget2016;7:57391-413 PMCID:PMC5302997

[127] Park HH,Park SY.RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment.Mol Cancer2021;20:107 PMCID:PMC8379748

[128] Allen IC,Moore CB.The NLRP3 inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA.Immunity2009;30:556-65 PMCID:PMC2803103

[129] Lee C,Her J,Seo D.Inflammasome as a promising therapeutic target for cancer.Life Sci2019;231:116593

[130] Hall K,Tinoco I Jr,van de Sande JH.“Z-RNA”-a left-handed RNA double helix.Nature1984;311:584-6

[131] Zhang T,Boyd DF.Influenza virus Z-RNAS induce ZBP1-mediated necroptosis.Cell2020;180:1115-1129.e13 PMCID:PMC7153753

[132] Zheng M.The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis).Immunol Rev2020;297:26-38 PMCID:PMC7811275

[133] Marcken M, Dhaliwal K, Danielsen AC, Gautron AS, Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection.Sci Signal2019;12:eaaw1347

[134] Bailey SR,Himes RA,Mehrotra S.Th17 cells in cancer: the ultimate identity crisis.Front Immunol2014;5:276 PMCID:PMC4060300

[135] Le Goffic R,Lagranderie M.Detrimental contribution of the Toll-like receptor (TLR)3 to influenza a virus-induced acute pneumonia.PLoS Pathog2006;2:e53 PMCID:PMC1475659

[136] Guillot L,Bloch S.Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza a virus.J Biol Chem2005;280:5571-80

[137] Bianchi F,Camisaschi C.TLR3 expression induces apoptosis in human non-small-cell lung cancer.Int J Mol Sci2020;21:1440 PMCID:PMC7073031

[138] Yang R,Xu T,Wu S.Emerging role of RNA sensors in tumor microenvironment and immunotherapy.J Hematol Oncol2022;15:43 PMCID:PMC9006576

[139] Weiss R,Zinngrebe J.IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.Cell Death Differ2013;20:823-33 PMCID:PMC3647237

[140] Lomphithak T,Mutirangura A.Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma.Cell Commun Signal2020;18:161 PMCID:PMC7545934

[141] Petersen SL,Minna JD.Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.Proc Natl Acad Sci USA2010;107:11936-41 PMCID:PMC2900705

[142] Olschläger V,Fischer T.Lung-specific expression of active Raf kinase results in increased mortality of influenza a virus-infected mice.Oncogene2004;23:6639-46

[143] Ji ZX,Liu XF.NS1: a key protein in the “game” between influenza a virus and host in innate immunity.Front Cell Infect Microbiol2021;11:670177 PMCID:PMC8315046

[144] García-Sastre A.Induction and evasion of type I interferon responses by influenza viruses.Virus Res2011;162:12-8 PMCID:PMC3640439

[145] Tisoncik JR,Burmakina S.The NS1 protein of influenza a virus suppresses interferon-regulated activation of antigen-presentation and immune-proteasome pathways.J Gen Virol2011;92:2093-104 PMCID:PMC3353386

[146] Baskin CR,García-Sastre A.Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.J Virol2007;81:11817-27 PMCID:PMC2168783

[147] Muster T,Sachet M.Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants.Int J Cancer2004;110:15-21

[148] van Rikxoort M,Wolschek M.Oncolytic effects of a novel influenza a virus expressing interleukin-15 from the NS reading frame.PLoS One2012;7:e36506 PMCID:PMC3341362

[149] Haye K,Moran T,Fernandez-Sesma A.The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells.J Virol2009;83:6849-62 PMCID:PMC2698524

[150] Hock K,Kuznetsova I.Oncolytic influenza a virus expressing interleukin-15 decreases tumor growth in vivo.Surgery2017;161:735-46

[151] Kabiljo J,Bergmann M.From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.Cell Death Discov2020;6:48 PMCID:PMC7288254

[152] Geiss GK,Tumpey TM.Cellular transcriptional profiling in influenza a virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza.Proc Natl Acad Sci USA2002;99:10736-41 PMCID:PMC125029

[153] Raja J,Gettinger SN,Kim HS.Oncolytic virus immunotherapy: future prospects for oncology.J Immunother Cancer2018;6:140 PMCID:PMC6280382

[154] Boorjian SA,Konety BR.Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.Lancet Oncol2021;22:107-17

[155] Evgin L,Tonne J.Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.Sci Transl Med2022;14:eabn2231 PMCID:PMC9297825

[156] Tanoue K,Watanabe N.Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors.Cancer Res2017;77:2040-51 PMCID:PMC5392365

[157] Watanabe K,Da T.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.JCI Insight2018;3:e99573 PMCID:PMC5928866

[158] Tang X,Ma J.Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.Cancer Lett2020;487:1-9

[159] Svensson-Arvelund J,Pantsulaia G.Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.Nat Commun2022;13:7149 PMCID:PMC9684150

[160] Guo ZS,Guo Z.Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.J Immunother Cancer2019;7:6 PMCID:PMC6325819

[161] Moehler M,Lee HC.Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).Oncoimmunology2019;8:1615817 PMCID:PMC6682346

[162] Vijayakumar G,Goff PH.Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.EBioMedicine2019;49:96-105 PMCID:PMC6945240

[163] Yamada T,Iwai M,Todo T.Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation.Mol Ther Oncolytics2020;18:535-45 PMCID:PMC7501409

[164] Jarnagin WR,Klimstra D.Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.Cancer Gene Ther2003;10:215-23

[165] Niavarani SR,Boudaud M,Tai LH.Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8⁺ T-cell functionality.J Immunother Cancer2020;8:e000465 PMCID:PMC7073779

[166] Bai F,Tian H.Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.Immunol Lett2014;159:36-46

[167] Xu X,Yu X.Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.Virus Res2017;233:35-41

[168] Syed Najmuddin SUF,Tan SW.Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice.PeerJ2020;8:e9761 PMCID:PMC7731658

[169] Vijayakumar G,Palese P.Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines.J Virol2020;94 PMCID:PMC7000961

[170] Bai FL,Tian H.Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Cancer Biol Ther2014;15:1226-38 PMCID:PMC4128865

[171] Tian L,Jiang S.Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.Gene Ther2023;30:64-74

[172] Zamarin D,Ricca J.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Nat Commun2017;8:14340 PMCID:PMC5316835

[173] Harper J,Travers J.Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity.Mol Cancer Ther2021;20:1723-34 PMCID:PMC9398146

[174] Huang FY,Dai SZ.A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.J Immunother Cancer2020;8:e000330 PMCID:PMC7410001

[175] Hamilton JR,Palese P.A Recombinant antibody-expressing influenza virus delays tumor growth in a mouse model.Cell Rep2018;22:1-7

[176] Penghui Y,Ruilan W.Oncolytic activity of a novel influenza a virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma.Hum Gene Ther2019;30:330-8

[177] Kuznetsova I,Aschacher T.Targeting an oncolytic influenza a virus to tumor tissue by elastase.Mol Ther Oncolytics2017;7:37-44 PMCID:PMC5633860